Meetings - The ASCO Post

Lung Cancer Progression-Free Survival With Immunotherapy Varies Significantly by Tumor-Mutation Subtype, Real-World Data Show

A real-world study of single-agent immune checkpoint inhibitors in driver-mutated non–small cell lung cancer (NSCLC) has demonstrated significant variation in progression-free survival between mutatio...

Immunotherapy

By Chase Doyle / November 25, 2020 / IASLC 2020 North America Conference on Lung Cancer

Use of Pembrolizumab in Advanced Pleural Mesothelioma: Results From KEYNOTE-158

The largest single-arm trial evaluating pembrolizumab in relapsed malignant pleural mesothelioma has demonstrated an “impressive” duration of response, according to a presentation during the virtual e...

Lung Cancer

Immunotherapy

By Chase Doyle / November 25, 2020 / IASLC 2020 North America Conference on Lung Cancer

Nivolumab Plus Ipilimumab in First-Line NSCLC: Two New Indications, Many More Questions

In May 2020, the combination of nivolumab and ipilimumab was approved by the U.S. Food and Drug Administration (FDA) for two separate indications in the first-line setting of advanced non–small cell ...

IASLC 2020 North America Conference on Lung Cancer

Lung Cancer Progression-Free Survival With Immunotherapy Varies Significantly by Tumor-Mutation Subtype, Real-World Data Show

Use of Pembrolizumab in Advanced Pleural Mesothelioma: Results From KEYNOTE-158

Nivolumab Plus Ipilimumab in First-Line NSCLC: Two New Indications, Many More Questions

Nivolumab With or Without Ipilimumab in Recurrent or Metastatic Cervical Cancer

Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status

Cabozantinib in Metastatic Pheochromocytomas or Paragangliomas

Propofol-Based Anesthesia May Offer Improved Detection of Serrated Polyps During Colonoscopy

Observing a Healthy Diet May Reduce Risk of Cardiovascular Disease in Breast Cancer Survivors